XBIO Xenetic Biosciences Inc.

1.33
+0.08  (+6%)
Previous Close 1.25
Open 1.28
Price To Book 0.48
Market Cap 7,654,338
Shares 5,755,141
Volume 578,408
Short Ratio
Av. Daily Volume 757,695
Stock charts supplied by TradingView

NewsSee all news

  1. Xenetic Biosciences, Inc. Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    - Company ramps up activities to execute XCART's preclinical and regulatory strategy -- Cash runway expected to fund Company through preclinical advancements towards IND filing -FRAMINGHAM, MA / ACCESSWIRE / November

  2. Xenetic Biosciences, Inc. Provides Business Outlook

    Recent completion of acquisition of innovative CAR T technology platform (XCART) has the potential to drive significant value for shareholders Management working with KOLs and subject matter experts to formalize XCART

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 enrolment closed in March 2019 due to slow enrolment.
XBIO-101
Endometrial cancer

Latest News

  1. Xenetic Biosciences, Inc. Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    - Company ramps up activities to execute XCART's preclinical and regulatory strategy -- Cash runway expected to fund Company through preclinical advancements towards IND filing -FRAMINGHAM, MA / ACCESSWIRE / November

  2. Xenetic Biosciences, Inc. Provides Business Outlook

    Recent completion of acquisition of innovative CAR T technology platform (XCART) has the potential to drive significant value for shareholders Management working with KOLs and subject matter experts to formalize XCART